SUBSCRIBE
SUBSCRIBE

Biora Therapeutics

IN THE PRESS
Policy
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023
January 9, 2023
 · 
8 min read
Biotech Beach
Biora Therapeutics Announces Reverse Stock Split
December 30, 2022
 · 
4 min read
Biotech Beach
Biora Therapeutics Announces Two Poster Presentations at the Crohn’s & Colitis Congress
December 8, 2022
 · 
3 min read
Biotech Beach
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial Development
November 29, 2022
 · 
4 min read
Business
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial Results
November 14, 2022
 · 
11 min read
Business
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update
November 7, 2022
 · 
3 min read
Biotech Beach
Biora Therapeutics Announces $9.75 Million Direct Offering
November 7, 2022
 · 
6 min read
Biotech Beach
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
October 27, 2022
 · 
3 min read
Biotech Beach
Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis Patients
October 25, 2022
 · 
7 min read
Biotech Beach
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022Presents Results on Device Performance Studies in Humans for Targeted Therapeutics Platform
October 24, 2022
 · 
5 min read
Load More
JOBS